[Centromere antibodies and antibodies against Scl 70 nucleoprotein in progressive XXXX . Diagnostic and prognostic significance].

@entity1 @entity8721 @entity2407 @entity2631 @entity4067 @entity730 @entity1463 @entity221 @entity785
Frequency and diagnostic significance of two @entity2631 -specific antinuclear antibodies were examined in 104 @entity1 with progressive @entity785 (PSS). Antibodies against an antigen in the centromere region of chromosomes (centromere antibodies) were demonstrated by indirect immuno-fluorescence on HEp-2 cells in 18 @entity1 (17%) and antibodies against Scl-70 nucleoprotein (Scl-70 antibodies) by gel precipitation with soluble nuclear extracts (ENA) in 21 @entity1 (20%). In none of the @entity1 did both antibodies occur. In @entity1 with Scl-70 antibodies severe @entity221 was predominant with extensive @entity1463 in 86%, lung involvement in 85% and joint involvement in 89%. Humoral inflammatory signs were marked in this group. @entity1 with centromere antibodies predominantly had acroscleroderma (56%) with subcutaneous @entity730 (83%) and @entity8721 (83%), as known from the @entity4067 . Humoral immune phenomena were rare. With regard to @entity2407 , involvement of the oesophagus, age and the duration of disease, there was no difference between the two groups. On the other hand, in @entity1 with centromere antibodies lung involvement (22%) and joint involvement (35%) was significantly less common (P less than 0.01) than in all other @entity2631 patients. Centromere antibodies and Scl-70 antibodies, which can be demonstrated already in the symptom-poor early phase of PSS, can thus be used as diagnostic parameters for different forms of PSS with differences in the degree of skin and organ involvement.
